This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:starting:physician:reluctant [04.29.2019] – [Specific research] sallieq | home:starting:physician:reluctant [04.30.2019] – [Specific research] sallieq | ||
---|---|---|---|
Line 272: | Line 272: | ||
the volume of larger atherosclerotic plaques (({{pubmed> | the volume of larger atherosclerotic plaques (({{pubmed> | ||
+ | Observations suggest a positive role in a potentially lower rate of coronary atheroma progression through the administration of olmesartan, an angiotension-II receptor blocking agent, for patients with stable angina pectoris. | ||
+ | |||
+ | This study showed that olmesartan reduces angiotensin II and aldosterone levels more effectively than azilsartan. | ||
improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed> | improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed> | ||
Line 294: | Line 297: | ||
{{section>: | {{section>: | ||
- | {{tag> | + | {{tag> |
===== Notes and comments ===== | ===== Notes and comments ===== |